Look past the first advertised price

The September 26, 2026 library review found that many sampled online services charged a membership while billing medicine separately. Some advertised an introductory month. That was a sample of advertised offers, not a measure of every service.

• What is included in the care fee?
• Is the medicine billed by the same business or separately?
• Are tests, follow-up and delivery included?
• What changes after the introductory offer?
• What is the cancellation and refund policy?

Give every price its label

A list price is a published manufacturer figure. Cash prices apply to payments made without an insurance claim. Copay means the portion a coverage arrangement leaves for you to pay. Those figures answer different questions.

For the maker’s cash offers checked September 26, 2026, $149 was the low end and $499 the high end of the monthly semaglutide prices. Each price level depended on the brand, whether it was a tablet or injection, and its strength, meaning the amount of medicine it contains. The lowest injection offer was introductory and covered only the first two monthly fills for eligible new patients.

• Semaglutide tablets (Wegovy or Ozempic): $149, $199 or $299 a month, depending on strength.
• Wegovy injections: $199 a month during the eligible introductory period, then $349; the Wegovy HD version was $399 a month.
• Ozempic injections: $199 a month during the eligible introductory period, then $349 or $499, depending on strength.

A December 31, 2026 deadline appeared in several of those terms. The maker could change or cancel its program. These are dated comparison figures, not a price promised for a future prescription.

• Request a cash quote for the named medicine.
• Ask how the price changes after the introductory period.
• Ask what quantity the quoted month includes.
• Ask how cash payments affect the deductible, the amount paid before certain plan benefits begin.

The maker’s recorded list figure for semaglutide (Wegovy) was about $1,349 for a package on September 26, 2026. That is a list figure, not an estimate of your personal bill.

With those cash offers, spending brought no credit against an insurance plan’s deductible or its cap on personal spending.

Ask the plan about the actual use

For Medicare drug coverage, the reason for care matters. As of September 26, 2026, some uses for diabetes, heart risk and MASH could qualify for Part D, Medicare’s prescription-drug coverage, subject to plan rules. MASH is a form of fatty liver disease with inflammation. The covered liver use has further limits.

Being eligible for coverage is only the first step. The plan still has to approve a request. A formulary is the plan’s drug list. Prior authorization means the plan needs to approve coverage before it pays.

• Is this exact product on my plan’s drug list for the proposed use?
• What records does the plan need for prior authorization?
• What would I pay if it approves the request?
• What is the next step if coverage is denied?

Know which Medicare route is being discussed

A separate temporary route is called the Medicare GLP-1 Bridge. In 2026, a separate Bridge service handled coverage requests and payments to pharmacies. Ask your prescriber how to submit a request to the Bridge. The September 26, 2026 record gave a $50 monthly copay for qualifying people. Its start was July 1, 2026; the scheduled end was December 31, 2027.

For semaglutide used for weight reduction, the Bridge included Wegovy injections and tablets, not semaglutide (Ozempic). A prescription and prior authorization were still required, with specific health and plan criteria.

People with the listed Part D-covered conditions are directed to the usual Part D route instead. The Bridge is not blanket weight-loss coverage for everyone enrolled in Medicare.

• Which coverage route applies to the reason for my prescription?
• Who submits the coverage request?
• What costs continue while the request is being reviewed?

Keep the dated estimate and the coverage answer together. Before committing, ask the service to put the ongoing cost in writing. That gives you something concrete to revisit if the next bill differs.